Replies to post #103535 on Cytodyn Inc (CYDY)

[All-Bidness]

I think with the safety profile being 64% better than placebo, the efficacy has to be there as well. We've seen viral load reduction in eIND patients. NP stated again there was a statistical significance and more. Dr J. in over 300 clinical trails hasn't seen results that Leronlimab was able to produce.

I would think we have to be better than the current SOC, which should get us EUA for m/m. I'm hoping once the FDA sees the complied data, and knowing that the S/C trails looked good, they will allow for earlier interim.

[Badge04]

The target is statistically significant. Good versus great is not determined in these trials. If the results show that leronlimab is better than standard of care, that’s a winner. Especially with what we’ve been shown from a safety perspective.

[JustAguy22]

Leronlimab is going to be standard of care, and show tremendous efficacy. It just may be that the size and design of this trial isn't perfect.